This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Dermatology  • Dermatologic Disorders  • Dermatologic Disorders, Other  • Dermatologic Procedures  • Immunotherapy  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Report of 4 Cases and Review of the Literature

Gianluca Vecchietti, MD; Katrin Kerl, MD; Christa Prins, MD; Gürkan Kaya, MD, PhD; Jean-Hilaire Saurat, MD; Lars E. French, MD

Arch Dermatol. 2006;142:213-217.

Background  High-dose intravenous immunoglobulins (IVIGs) are increasingly used to treat inflammatory and/or autoimmune disorders. In dermatology, they provide therapeutic benefit in Kawasaki disease and certain cases of dermatomyositis. While most adverse effects following IVIG treatment are not severe, occasionally more severe adverse effects occur, including anaphylactic reactions and acute, usually transient, renal failure.

Observations  We report 4 cases of a characteristic severe extensive eczematous reaction that occurred approximately 10 days after IVIG infusion for polyradiculoneuritis. In all cases, onset was characterized by dyshidrotic lesions on the palms, rapidly followed by pruriginous maculopapular lesions involving the whole body. All patients were treated with topical and/or systemic steroids, and complete resolution of skin lesions was observed within 1 month. To date, 33 cases of cutaneous rash following IVIG infusion have been reported in the literature, mostly in neurology journals, and the features are identical to those reported herein.

Conclusions  Severe eczematous skin reaction with a characteristic initial localization to the palms and/or soles that then extends to the rest of the body is a rare but characteristic adverse effect of high-dose IVIG therapy. Although the precise mechanism of this cutaneous eruption remains to be elucidated, its occurrence within days of IVIG infusion, its characteristic distribution at onset, and its clinical course should be recognized by dermatologists.

Author Affiliations: Department of Dermatology, University of Geneva, Geneva, Switzerland.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Vesicular Eczema After Intravenous Immunoglobulin Therapy for Treatment of Stevens-Johnson Syndrome
Priya K. Young, Sun Young Ruggeri, Sheila Galbraith, and Beth A. Drolet
Arch Dermatol. 2006;142(2):247-248.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Frequency of Adverse Events Associated with Intravenous Immunoglobulin Therapy in Patients with Pemphigus or Pemphigoid
Gurcan and Ahmed
The Annals of Pharmacotherapy 2007;41:1604-1610.
ABSTRACT | FULL TEXT  

Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders
Gurcan and Ahmed
The Annals of Pharmacotherapy 2007;41:812-823.
ABSTRACT | FULL TEXT  

Cosmetic medical devices and their FDA regulation.
Newburger
Arch Dermatol 2006;142:225-228.
FULL TEXT